Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs IV PPIs for Peptic Ulcer Rebleeding
NCT05005910Phase 1Completed
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in Peptic ulcer hemorrhage (PUB) (2 arms). Primary endpoint: Rebleeding rate at 30 days. Started Sep 2021; status: completed.
02
Drugs
vonoprazan
03
Conditions
Peptic ulcer hemorrhage (PUB)
Beyond the preview
Go deeper on NCT05005910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005910.